ASTERA LABS INC (ALAB)

US04626A1034 - Common Stock

61.22  +8.26 (+15.6%)

After market: 61.48 +0.26 (+0.42%)

Fundamental Rating

4

Overall ALAB gets a fundamental rating of 4 out of 10. We evaluated ALAB against 109 industry peers in the Semiconductors & Semiconductor Equipment industry. ALAB has a great financial health rating, but its profitability evaluates not so good. ALAB is valied quite expensively at the moment, while it does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

ALAB had negative earnings in the past year.

1.2 Ratios

With a Return On Assets value of -2.87%, ALAB is not doing good in the industry: 63.30% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -3.11%, ALAB is doing worse than 62.39% of the companies in the same industry.
Industry RankSector Rank
ROA -2.87%
ROE -3.11%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 68.94%, ALAB belongs to the best of the industry, outperforming 91.74% of the companies in the same industry.
ALAB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

9

2. Health

2.1 Basic Checks

ALAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALAB remains at a similar level compared to 1 year ago.
There is no outstanding debt for ALAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 82.66 indicates that ALAB is not in any danger for bankruptcy at the moment.
ALAB's Altman-Z score of 82.66 is amongst the best of the industry. ALAB outperforms 99.08% of its industry peers.
There is no outstanding debt for ALAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 82.66
ROIC/WACCN/A
WACC13.16%

2.3 Liquidity

A Current Ratio of 13.91 indicates that ALAB has no problem at all paying its short term obligations.
ALAB has a better Current ratio (13.91) than 98.17% of its industry peers.
ALAB has a Quick Ratio of 13.46. This indicates that ALAB is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 13.46, ALAB belongs to the best of the industry, outperforming 98.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.91
Quick Ratio 13.46

5

3. Growth

3.1 Past

ALAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.00%, which is quite impressive.
Looking at the last year, ALAB shows a very strong growth in Revenue. The Revenue has grown by 44.97%.
EPS 1Y (TTM)55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)44.97%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ALAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 77.08% yearly.
Based on estimates for the next years, ALAB will show a very strong growth in Revenue. The Revenue will grow by 63.36% on average per year.
EPS Next Y433.13%
EPS Next 2Y160.26%
EPS Next 3Y104.89%
EPS Next 5Y77.08%
Revenue Next Year203.19%
Revenue Next 2Y112.44%
Revenue Next 3Y81.52%
Revenue Next 5Y63.36%

3.3 Evolution

2

4. Valuation

4.1 Price/Earnings Ratio

ALAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 74.49, which means the current valuation is very expensive for ALAB.
Based on the Price/Forward Earnings ratio, ALAB is valued a bit more expensive than the industry average as 62.39% of the companies are valued more cheaply.
The average S&P500 Price/Forward Earnings ratio is at 22.44. ALAB is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 74.49

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ALAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ALAB's earnings are expected to grow with 104.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y160.26%
EPS Next 3Y104.89%

0

5. Dividend

5.1 Amount

No dividends for ALAB!.
Industry RankSector Rank
Dividend Yield N/A

ASTERA LABS INC

NASDAQ:ALAB (10/9/2024, 8:00:00 PM)

After market: 61.48 +0.26 (+0.42%)

61.22

+8.26 (+15.6%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.59B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 74.49
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.87%
ROE -3.11%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 68.94%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 13.91
Quick Ratio 13.46
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)55%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y433.13%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)44.97%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y